Regeneron Pharmaceuticals Inc has said that the Covid-19 antibody drug combination it is developing both prevented and treated the disease in rhesus macaques and hamsters, adding to hope that it might work for people, SIA reports.
The US biotech company said on Monday in the animal study, which has not yet been peer reviewed, that the cocktail of two monoclonal antibodies was able to "almost completely block establishment of virus infection."
Regeneron said the cocktail was also able to minimise infection in a second study in which animals were infected with a much higher level of the virus. The prophylactic effect was greatly diminished with a lower dose of the drug, the company said. It said the results matched or exceeded effects recently shown in animal studies of vaccine candidates.
Bütün xəbərlər Facebook səhifəmizdə